Astellas’ XTANDI (Enzalutamide) Granted European Commission Approval for Use in Additional Recurrent Early Prostate ...
XTANDI is now the first and only novel hormone therapy available for the treatment of high-risk biochemical recurrent non-metastatic hormone-sensitive prostate cancer in the European Union (EU) XTANDI can be given alone or in combination with androgen …